Developing therapeutics for the treatment of multiple sclerosis - Wikidata - awgldk - TriplyDB

Developing therapeutics for the treatment of multiple sclerosis

Developing therapeutics for the treatment of multiple sclerosis

http://www.wikidata.org/entity/Q33946995

about

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.In Vitro Effects of Sodium Benzoate on Th1/Th2 Deviation in Patients with Multiple Sclerosis.Recent Advances on the Possible Neuroprotective Activities of Epstein-Barr Virus Oncogene BARF1 Protein in Chronic Inflammatory Disorders of Central Nervous System.Ginsenoside Rd ameliorates experimental autoimmune encephalomyelitis in C57BL/6 mice.Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts.

P2860

Q33641367-D8D1DCEF-0091-4D19-AE3E-74818ED6C5DB Q33810559-FDEEB874-A3B3-4203-A754-A68B90661779 Q35826151-D3553BFA-7316-44C3-A356-6CFBACC191DF Q35945171-7F1E55A1-4D18-47CA-BA01-404D125DEB31 Q37641562-3A1B9946-CB20-48A8-A757-CA3F505CA46E Q37767357-90AB6A4F-EA55-4DB6-A6F5-9C45D6143D2B Q39406942-FA8C6470-969F-4B76-84B5-C62B16C8EA38 Q41136819-2118E445-D23D-4D4B-AC7A-ACE28881B80F Q48792301-FF0A662C-79B4-4ED2-A7E9-AC6BB4F87F11 Q54565698-A7B93CCD-8892-4508-8BED-1C4A397588FE

P2860

Developing therapeutics for the treatment of multiple sclerosis

http://www.wikidata.org/entity/Q33946995

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Developing therapeutics for the treatment of multiple sclerosis

@ast

Developing therapeutics for the treatment of multiple sclerosis

@en

type

label

Developing therapeutics for the treatment of multiple sclerosis

@ast

Developing therapeutics for the treatment of multiple sclerosis

@en

prefLabel

Developing therapeutics for the treatment of multiple sclerosis

@ast

Developing therapeutics for the treatment of multiple sclerosis

@en

P1433

Q33946995-0D041467-64D0-48DE-AEDD-D3DEB1831041

P1476

Q33946995-DE1B8A20-5A5D-4427-83D9-270CAE4634EE

P2093

Q33946995-7A1B1B1C-CBE0-4205-B50B-BD008E63A6EC

P2860

Q33946995-03900ED5-72AB-4B0C-A798-0DBF842A6818

Q33946995-0E7333F1-289B-4605-B123-A421676E95F7

Q33946995-11C09B2E-9527-42A0-B8DC-BB42281904FE

Q33946995-1207B7EC-5F3A-4A88-91B6-1BAE1CCA70C7

Q33946995-1410D7D8-5557-4436-95BC-A1FEAD551006

Q33946995-15B244C7-8BF4-4E60-B850-B7281E3A70C8

Q33946995-19CEC4E0-43BA-4631-81ED-B23ED8C96830

Q33946995-19FF2977-0953-4DC3-A29F-0E119F0C4471

Q33946995-1D175BFF-C683-45D7-B7F2-506EECC1C492

Q33946995-1FE8F21E-F14A-429C-9476-244595945B8C

P304

Q33946995-9E8A303F-8C5C-46A1-B1B7-A023F5A2EBCE

P31

Q33946995-FA69622E-E004-4A3A-BB66-873539B7CB17

P356

Q33946995-76F2E864-F8F2-4137-82EB-6271192B572F

P433

Q33946995-C83B1579-B4FC-43A9-B254-639D5C6CAFAD

P478

Q33946995-79ECE6F6-2B17-48D1-86A7-997C692696C8

P577

Q33946995-E4DA2BE0-9E13-4989-A6EE-545B8B73AAAB

P5875

Q33946995-723AC7E9-3AD6-49A9-8B40-F0CD077EE4A8

P698

Q33946995-6FA4ED68-E9CA-42DF-8F7F-B5FC91653CB8

P921

Q33946995-633714B5-C1BF-4E42-ACCF-79188A1C58D6

P932

Q33946995-6CFE290E-864D-4B81-8C14-87F1AC7F9535

P356

NEURORX.2.4.638

P1433

P1476

Developing therapeutics for the treatment of multiple sclerosis

@en

P2093

David J Virley

http://www.w3.org/2001/XMLSchema#string

P2860

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy

Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology

The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination

New immunosuppressants with potential implication in multiple sclerosis

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

Adhesion Molecules in Multiple Sclerosis

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

Diffusion tensor imaging in spinal cord: methods and applications - a review.

Non-invasive measurement of brain damage in a primate model of multiple sclerosis.

P304

638-649

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1602/NEURORX.2.4.638

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7288563

http://www.w3.org/2001/XMLSchema#string

P698

16489371

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

1201321

http://www.w3.org/2001/XMLSchema#string